Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

2.
3.

Efficacy and safety of rosuvastatin in the management of dyslipidemia.

Rubba P, Marotta G, Gentile M.

Vasc Health Risk Manag. 2009;5(1):343-52. Epub 2009 Apr 8. Review.

5.
6.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548
7.

Moving toward new statin guidelines in a post-JUPITER world: principles to consider.

Ridker PM.

Curr Atheroscler Rep. 2009 Jul;11(4):249-56. Review.

PMID:
19500487
8.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
9.
10.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
11.

Statins for primary prevention of venous thromboembolism.

Li L, Zhang P, Tian JH, Yang K.

Cochrane Database Syst Rev. 2014 Dec 18;(12):CD008203. doi: 10.1002/14651858.CD008203.pub3. Review.

PMID:
25518837
12.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
14.

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

Kostapanos MS, Milionis HJ, Elisaf MS.

Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Review.

PMID:
20104931
15.

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.

Narla V, Blaha MJ, Blumenthal RS, Michos ED.

Vasc Health Risk Manag. 2009;5:1033-42. Epub 2009 Dec 29. Review.

16.

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.

Long SB, Blaha MJ, Blumenthal RS, Michos ED.

Clin Interv Aging. 2011;6:27-35. doi: 10.2147/CIA.S8101. Epub 2010 Dec 22. Review.

17.

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Kostapanos MS, Rizos CV, Elisaf MS.

Drug Saf. 2014 Jul;37(7):481-500. doi: 10.1007/s40264-014-0169-4. Review.

PMID:
24788803
18.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004816.

19.

[Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Diseases].

Drapkina OM, Eliashevich SO.

Kardiologiia. 2015;55(2):72-81. Review. Russian.

PMID:
26164992
20.

[Efficacy of lipid correcting therapy with the use of rosuvastatin].

Ivleva AIa.

Kardiologiia. 2005;45(6):71-80. Review. Russian. No abstract available.

PMID:
16007037

Supplemental Content

Support Center